A new mouse model mimicking the liver symptoms of myotonic dystrophy type 1 — the most prevalent form of adult-onset muscular dystrophy — provides insight into why patients develop fatty liver disease and display hypersensitivity to medications, making treatment difficult. The new model opens avenues for screening new medications for liver toxicity prior to patient trials.
Categories
Recent Posts
- Izzy Camilleri Merges High Fashion and Adaptive Clothing Design
- My late brother was my greatest teacher, in life and Duchenne
- LGMD gene therapy gets FDA orphan drug designation
- Capricor plans Deramiocel resubmission to the FDA, pursuing both cardiac and skeletal muscle indications in Duchenne
- MDA Ambassador Guest Blog: Life Lessons on My Journey with Becker Muscular Dystrophy